Argenica Therapeutics (ASX:AGN) Cash-to-Debt : No Debt ⁽¹⁾ (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Argenica Therapeutics Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Argenica Therapeutics's cash to debt ratio for the quarter that ended in Dec. 2023 was No Debt ⁽¹⁾.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Argenica Therapeutics could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Argenica Therapeutics's Cash-to-Debt or its related term are showing as below:

ASX:AGN' s Cash-to-Debt Range Over the Past 10 Years
Min: No Debt Med: No Debt Max: No Debt
Current: No Debt

During the past 3 years, Argenica Therapeutics's highest Cash to Debt Ratio was No Debt. The lowest was No Debt. And the median was No Debt.

ASX:AGN's Cash-to-Debt is ranked better than
99.8% of 1493 companies
in the Biotechnology industry
Industry Median: 6.89 vs ASX:AGN: No Debt

Argenica Therapeutics Cash-to-Debt Historical Data

The historical data trend for Argenica Therapeutics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Argenica Therapeutics Cash-to-Debt Chart

Argenica Therapeutics Annual Data

Trend

Jun21

Jun22

Jun23

Cash-to-Debt

No Debt

Argenica Therapeutics Semi-Annual Data
	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial			No Debt	No Debt	No Debt	No Debt	No Debt

Competitive Comparison of Argenica Therapeutics's Cash-to-Debt

For the Biotechnology subindustry, Argenica Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Argenica Therapeutics's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Argenica Therapeutics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Argenica Therapeutics's Cash-to-Debt falls into.

Argenica Therapeutics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Argenica Therapeutics's Cash to Debt Ratio for the fiscal year that ended in Jun. 2023 is calculated as:

Argenica Therapeutics had no debt ⁽¹⁾.

Argenica Therapeutics's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Argenica Therapeutics had no debt ⁽¹⁾.

Argenica Therapeutics (ASX:AGN) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Argenica Therapeutics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Argenica Therapeutics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Argenica Therapeutics (ASX:AGN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Argenica Therapeutics Ltd (ASX:AGN) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

117 Broadway, Unit 4, Nedlands, WA, AUS, 6009

Website

https://www.argenica.com.au

Argenica Therapeutics Ltd is engaged in the development and commercialization of novel drug candidates. Its ARG007 drug improves outcomes in pre-clinical stroke models and is in the process of being verified for its safety and toxicology before commencing Phase 1 clinical trials in humans.

Argenica Therapeutics (ASX:AGN) Headlines

No Headlines

Argenica Therapeutics (ASX:AGN) Cash-to-Debt : No Debt (1) (As of Dec. 2023)